Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2307400 | 1.00 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2NPC1UCHL1LMNA | |
| SCHEMBL6941435 | 0.95 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2NPC1UCHL1LMNA | |
| SCHEMBL6948605 | 0.95 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2NPC1UCHL1LMNA | |
| SCHEMBL8389716 | 0.95 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2NPC1UCHL1LMNA | |
| SCHEMBL25428390 | 0.87 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2NPC1UCHL1LMNA | |
| SCHEMBL30987668 | 0.85 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2NPC1UCHL1LMNA | |
| SCHEMBL31048244 | 0.85 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2NPC1UCHL1LMNA | |
| SCHEMBL3156952 | 0.85 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2NPC1UCHL1LMNA | |
| SCHEMBL18455856 | 0.85 | FKBP1A (0.39) | HSD17B10SMN1; SMN2NPC1UCHL1MEN1 | |
| SCHEMBL18787688 | 0.84 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2NPC1UCHL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838900-B1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-20170342079-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| US-20170342079-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| US-20170029427-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-20170029427-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9504689-B2 | Compounds and methods for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9504689-B2 | Compounds and methods for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150238501-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150238501-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2015-08-27 | — | — | US | disclosed |
| US-8980878-B2 | Compounds and methods for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980878-B2 | Compounds and methods for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130273037-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130273037-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130273037-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | ZC3HAV1, SARS1, MAVS | HSD17B10 1128/4885SMN1; SMN2 472/4885NPC1 100/4885 |
| US-20150238501-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | ZC3HAV1, SARS1, MAVS | HSD17B10 1128/4885SMN1; SMN2 472/4885NPC1 100/4885 |
| US-20170342079-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | ZC3HAV1, SARS1, MAVS | HSD17B10 1128/4885SMN1; SMN2 472/4885NPC1 100/4885 |
| US-20170029427-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | ZC3HAV1, SARS1, MAVS | HSD17B10 1128/4885SMN1; SMN2 472/4885NPC1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.